Abbott Laboratories is presenting a complex case for value seekers as its dividend yield climbs to a ten-year high, reflecting a stock price weighed down by the $21 billion Exact Sciences integration and ongoing legal struggles.
Abbott is trading around $83 following a post-earnings pullback, pushing its dividend yield above 3% on a $2.52 annual payout that analysts believe has presented a rare buying opportunity. Investors are now weighing the attractiveness of the current entry point, given the dividend setup, against the Exact Sciences acquisition, which is projected to be $0.20 dilutive to 2026 earnings, and the unpredictable trajectory of NEC litigation, where the threat of punitive damages from pending cases looms over the balance sheet.
Abbott stands out as a premier Dividend King, having increased its payout for 54 consecutive years. The company recently issued its 408th straight quarterly dividend, a streak dating back to 1924 that has earned it a reputation among market observers for dividend reliability. RBC Capital noted, "ABT is committed to creating substantial shareholder value through strategic capital allocation. ABT remains committed to its dividends, which have increased for over 50 consecutive years, while continuing to invest for growth with internal R&D and opportunistic M&A."
One of the most significant overhangs for the stock is the mounting litigation regarding Abbott’s infant formula. Last week, a Chicago jury awarded $70 million to four mothers who alleged the company concealed the risk that its cow-milk-based formula could cause necrotizing enterocolitis (NEC), a life-threatening bowel disease in premature infants. Jurors determined that Abbott was aware of the risks but continued to market the product to neonatal intensive care units. The total award included $53 million in compensatory damages and $17 million in punitive damages.
Abbott said it strongly disagrees, plans to appeal, and argues that medical experts and regulators consider the products safe and necessary. This is Abbott’s second trial loss in the infant formula litigation, and it now faces more than 1,700 similar lawsuits — 784 in federal court in Illinois and the rest in state court, mostly in Illinois.
Jefferies observed in a recent note to clients that ongoing NEC litigation against Abbott Laboratories and Reckitt Benckiser remains a manageable risk despite mounting legal battles over infant formula products, with analysts estimating potential settlements could range between $2 billion and $7 billion.
The brokerage noted that while state court cases have so far favored plaintiffs, federal multidistrict litigation (MDL) proceedings have largely gone in favor of the defendants. Jefferies said a second wave of MDL bellwether trials scheduled over the next six to nine months could become a natural window for settlement discussions.
Jefferies maintained that Abbott Laboratories is financially well-positioned to absorb a settlement if required, highlighting the company’s roughly $7.3 billion cash balance and strong cash generation. The firm kept its base-case liability estimate for Abbott at $1 billion to $2 billion, representing less than 2% of the company’s market capitalization.
The report comes as investors continue to monitor diverging outcomes between state and federal cases. State courts in Illinois and Missouri have delivered several large plaintiff verdicts, including a recent case against Abbott involving approximately $95 million in compensatory damages and about $400 million in punitive damages
However, Jefferies noted that federal MDL cases have so far produced a 3-1 record in favor of Abbott and Reckitt. Analysts added that regulators, including the FDA, CDC and NIH, have stated there is no conclusive evidence directly linking cow’s milk-based formula to NEC, with prematurity considered the primary driver of the disease.
source https://www.investing.com/news/stock-market-news/abbotts-dividend-yield-near-decade-peak-signaling-rare-buying-opportunity-4681600
